Mumbai, August 26, 2026: Tavexia Lifecare Limited has announced its expansion into the pharmaceutical sector as a new growth vertical, strengthening its presence across the broader healthcare and lifecare ecosystem.
The strategic move is aimed at diversifying the Company’s business portfolio and creating additional avenues for long-term growth, while its existing lifecare business continues to remain at the core of its operations.
As part of the expansion, Tavexia plans to explore opportunities across the pharmaceutical value chain, including pharmaceutical products, Active Pharmaceutical Ingredients (APIs), intermediates, specialty chemicals, nutraceuticals and related manufacturing opportunities.
The pharmaceutical vertical is expected to complement Tavexia’s existing operations and provide the Company with a broader platform to evaluate opportunities in product development, partnerships and manufacturing.
The expansion comes against the backdrop of strong growth in India’s pharmaceutical industry. The Indian pharmaceutical market is currently estimated at around US$60 billion and is projected to reach approximately US$130 billion by 2030. India’s pharmaceutical exports stood at around US$30.47 billion in FY2024-25, reflecting the country’s growing significance in global healthcare and pharmaceutical supply chains.
Commenting on the expansion, Mr. Mit Tarunkumar Brahmbhatt, Chairman and Managing Director, Tavexia Lifecare Limited, said: “Our core lifecare business remains central to Tavexia’s growth journey, and the addition of pharmaceuticals is a natural extension of our presence in the broader healthcare ecosystem. India’s pharmaceutical sector presents significant opportunities, and we see potential to build an additional growth engine alongside our existing operations. Our focus will remain on disciplined execution, developing sustainable business capabilities and creating long-term value for our shareholders and stakeholders.”
Tavexia will continue strengthening its existing lifecare operations while evaluating opportunities in the pharmaceutical sector based on market potential, commercial viability and long-term strategic value.
The addition of the pharmaceutical vertical is expected to broaden the Company’s addressable market and create a more diversified platform for future growth. Tavexia intends to adopt a calibrated approach to the new business, with a focus on building sustainable capabilities while maintaining its core positioning in the lifecare segment.